Oxford Drug Design, a pre-clinical stage therapeutics spinout from Oxford University, is discovering innovative small-molecule treatments against cancer and other major diseases. The company has a distinctive dual-core competencies platform of pioneering computational AI and machine learning methods integrated with comprehensive aminoacyl-tRNA synthetases (aaRS) capabilities. At the cutting edge of machine learning and AI applied to pre-clinical drug discovery in its internal programs, Oxford Drug Design also provides computational AI-based collaborative services to other therapeutic companies to advance their drug discovery efforts.